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and co-occurs with upregulation of
pro-inflammatory genes and downregulation of
genes involved in mitochondrial functions
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Abstract
Background: The transcription factor farnesoid X receptor (FXR) governs bile acid and energy homeostasis, is involved
in inflammation, and has protective functions in the liver. In the present study we investigated the effect of Fxr
deficiency in mouse precision cut liver slices (PCLS) exposed to a model hepatotoxicant cyclosporin A (CsA). It
was anticipated that Fxr deficiency could aggravate toxicity of CsA in PCLS and pinpoint to novel genes/processes
regulated by FXR.
Methods: To test this hypothesis, PCLS obtained from livers of wild type mice (WT-PCLS) and Fxr-knockout mice
(FXRKO-PCLS) were treated with 40 μM CsA for 24 h and 48 h. ATP and histological assays were applied to assess
the viability of PCLS. DNA microarrays combined with bioinformatics analysis were used to identify genes and
processes that were affected by CsA in WT-PCLS and/or FXRKO-PCLS. In addition, WT-PCLS and FXRKO-PCLS were
exposed to the endogenous FXR ligand chenodeoxycholic acid (CDCA) and subjected to q-PCR to determine whether
subsets of known FXR-targets and the identified genes were regulated upon FXR activation in an FXR-dependent
manner.
Results: No difference in viability was observed between WT-PCLS and FXRKO-PCLS upon CsA treatment.
Transcriptomics data analysis revealed that CsA significantly upregulated stress-response and inflammation and
significantly downregulated processes involved in lipid and glucose metabolism in WT-PCLS and FXRKO-PCLS.
However, only in FXRKO-PCLS, CsA upregulated additional pro-inflammatory genes and downregulated genes
related to mitochondrial functions. Furthermore, only in WT-PCLS, CDCA upregulated a subset of known FXR-target
genes as well as the regulator of inflammation and mitochondrial functions peroxisome proliferator- activated receptor
delta (Ppar delta).
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Conclusions: Although FXR governs energy metabolism, no major differences in response to CsA could be observed
between WT-PCLS and FXRKO-PCLS in regulation of processes involved in lipid and glucose metabolism. This finding
indicates that CsA does not directly affect FXR functions in relation to the above mentioned processes. However, the
more pronounced induction of pro-inflammatory genes and the downregulation of genes involved in mitochondrial
functions only in FXRKO-PCLS suggest that FXR deficiency aggravates CsA-induced inflammation and impairs
mitochondrial functions. Therefore, FXR can exert its hepatoprotective functions by controlling inflammation and
mitochondrial functions, possibly involving an FXR-PPAR delta cross-talk.
Keywords: Farnesoid X receptor (FXR), Precision cut liver slices (PCLS), Cyclosporine A, Hepatotoxicity, Mitochondrial
functions, Inflammation, Peroxisome proliferator-activated receptor δ (PPAR δ), Transcriptomics
Background
Farnesoid X receptor (Fxr) is highly expressed in liver,
intestine, kidney, adrenal glands and has a lower expres-
sion in white adipose tissue, pancreas, heart, and stomach
[1]. Upon the discovery that bile acids (BA) are endogen-
ous FXR agonists with chonedoexy cholic acid (CDCA)
being the most potent FXR agonist, the primary functions
of FXR were attributed to the maintenance of BA homeo-
stasis [2]. FXR, upon activation by binding of a ligand, di-
merizes either as a homodimer or as an heterodimer with
another member of the nuclear receptor superfamily,
retinoid X receptor (RXR), and binds to FXR response
elements (FXRE) in the promoter region of its target
genes to drive transcription [2]. FXR positively regulates
the expression of several genes coding transporters
and enzymes involved in BA homeostasis including bile
salt export pump (BSEP), bile acid-CoA:amino acid
N-acyltransferase (BAAT), or multidrug resistance protein
3 (MDR3). In addition, FXR can inhibit the expression
of some of its target genes, including cholesterol-7α-
hydroxylase (Cyp7a1), by a mechanism referred to as
trans-repression involving induction of other transcrip-
tion factors, such as small heterodimer partner (Shp).
Thus, in liver FXR upregulates its direct target gene Shp,
which in turn inhibits expression of the liver receptor
homolog (Lrh)-1, liver X receptor (Lxr), and hepatocyte
nuclear factor 4 α (Hnf4α), all necessary for constitutive
expression of Cyp7a1, coding a rate limiting enzyme in
the synthesis of BA from cholesterol [3] .
In recent years it has become evident that FXR, next
to its well established role in BA homeostasis, is also in-
volved in the maintenance of lipid and glucose metabol-
ism [2]. Consistent with these observations, Fxr-knockout
(KO) mice are dyslipidemic, with elevated plasma triglyc-
erides and cholesterol levels [4]. With regard to regulation
of glucose homeostasis, it was shown that Fxr-KO mice
display peripheral insulin resistance implying that FXR
is involved in regulation of insulin sensitivity and glu-
cose metabolism [3]. In line with these findings, FXR
was shown to regulate expression of the gluconeogenic
genes such as phosphoenolpyruvate carboxykinase (Pepck)
and glucose 6 phosphatase (G6Pase) [5, 6]. In addition to
its role in BA and energy homeostasis, FXR exerts hepato-
protective functions through its anti-inflammatory, anti-
fibrotic, anti-apoptotic, pro-regenerative, and detoxifying
features [7].
Due to the complexity of hepatic FXR signaling, involv-
ing entero-hepatic communication and interplay with
extrahepatic tissues [2], none of the current in vitro
models allow to study FXR functions in full. However,
it is possible to study mechanisms related to hepatic
FXR signaling in in vitro liver models. One such model
is represented by precision cut liver slices (PCLS). The
major advantage of PCLS, compared to mono-cultures
of hepatocytes, is the presence of parenchymal as well
as non-parenchymal liver cells, whose interactions are
important in the context of FXR signaling [8–11].
The objective of the present study was to investigate the
role of FXR in the liver under a hepatotoxic challenge.
It was anticipated that Fxr deficiency could aggravate
effects of the model hepatotoxic compound cyclosporine
A (CsA). CsA is an immunosuppressive drug commonly
applied after solid organ transplantation to prevent rejec-
tion [12]. The pharmacological properties of CsA are re-
lated to repression of the activity of the immune system
by interfering with T cell functioning [13, 14]. Adverse ef-
fects caused by CsA include hepatotoxicity that can lead
to the development of cholestasis [15], fatty liver [16], and
cardiovascular complications due to hyperlipidemia [17].
The primary mechanism of action underlying the hepato-
toxicity of CsA is prevention of the mitochondrial perme-
ability transition pore from opening leading to oxidative
stress and impairment of mitochondrial functions [18].
This is most likely followed by induction of NFκB signal-
ing driving expression of pro-inflammatory cytokines (e.g.
TNFα, Il1α, and Il1β) and endoplasmatic reticulum (ER)
stress, causing a disturbed vesicles formation necessary for
protein, lipid, and bile acid trafficking [11, 19]. In addition,
it was reported that expression of Fxr and its target genes
was de-regulated upon treatment with CsA in different
human and rodent in vitro liver models as well as rodents
in vivo [11, 20–22].
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In order to study the effect of Fxr deficiency under
hepatotoxic challenge, mouse PCLS obtained from livers
of wild type (WT) and Fxr-KO mice (referred to as
WT-PCLS and FXRKO-PCLS, respectively) were treated
with 40 μM CsA. ATP and histological assays were applied
to assess the viability of the PCLS after 24 h and 48 h.
DNA microarrays combined with bioinformatics analysis
were used to identify genes and processes (i.e. pathways
and gene ontology (GO) terms) that were affected in
WT-PCLS and/or FXRKO-PCLS upon 24 h treatment
with CsA. The genes and processes commonly affected
in WT-PCLS and FXRKO-PCLS were considered as CsA
targets, whose regulation was not dependent on FXR. The
genes and processes that were significantly affected in
either WT-PCLS or FXRKO-PCLS after CsA treatment
were considered to be regulated in an FXR-dependent
manner. To verify whether regulation of some of the
identified genes was FXR-dependent, WT-PCLS and
FXRKO-PCLS were exposed for 24 h to the endogenous




Cyclosporin A (CsA), chonedoexy cholic acid (CDCA),
and bovine serum albumin (BSA) were purchased from
Sigma (Sigma, Zwijndrecht, the Netherlands). Williams E
medium (WEM), Glutamax, penicillin/streptomycin (pen/
strep), D-Glucose, phosphate buffered saline (PBS) were
obtained from Invitrogen (Invitrogen, Bleiswijk, the
Netherlands).
Preparation and incubation of liver slices
12-weeks old male C57BL/6 mice and 12-weeks old
FXRKO mice on a C57BL/6 mice background were bred
at the animal facility of University Medical Centre Gro-
ningen (UMCG), the Netherlands. FXRKO mice were
constructed and tested as described previously [23]. After
arrival to the animal facility of Wageningen University, an-
imals were kept for 2 weeks at a housing temperature of
22 °C and at a relative humidity of 30–70 %. The lighting
cycle was 12-h light and 12-h dark. At the age of 24 weeks
animals were sacrificed by an overdose of isoflurane. The
treatment protocol was approved by the Ethical Commit-
tee for Animal Experiments of Wageningen University.
Immediately after the animals were killed, the liver was
perfused with PBS and placed in ice-cold Krebs–Henseleit
buffer (KHB) (pH 7.4, supplemented with 11 mM glucose).
Liver tissue was transported to the laboratory within
approximately 30 min and cylindrical liver cores were
produced using a surgical biopsy punch with diameter
of 5 mm (KAI, SynErgo Europe, Romania). Liver cores
were placed in a Krumdieck tissue slicer (Alabama Research
and Development, Munford, AL, USA) filled with ice-cold
KHB aerated with carbogen and supplemented with 11 mM
glucose. Slices with a diameter of 5 mm, a thickness of
0.2 mm and a weight of approximately 6 mg were pre-
pared. Immediately after preparation, slices were trans-
ferred into culture plates filled with pre-warmed (37 °C)
WEM supplemented with pen/strep. Three liver slices
were pre-cultured in one well of the 6-well plate filled
with 4 ml of WEM for one hour with continuous agita-
tion (70 rpm). Incubations were performed in an oxy-
gen controlled incubator (Galaxy 48 R, New Brunswick,
Nijmegen, the Netherlands) at 80 % of oxygen, 5 %
CO2,and the remaining gas volume was filled up to
95 % with N2. After one hour of pre-incubation, media
were removed and replaced with fresh media contain-
ing test compounds or appropriate solvents. After incu-
bations, samples were snap-frozen in liquid nitrogen
and stored in −80 °C for further analysis. Samples ded-
icated to histology were stored in 4 % formaldehyde at
room temperature.
PCLS exposure
For all exposure experiments, PCLS were obtained from
5 WT and 5 FXRKO mice. Slices obtained from each
biological replicate were cultured apart and each culture
consisted of 3 co-incubated slices. The exposure experi-
ments were performed at 2 days; at day1, PCLS obtained
from livers of 3 WT mice and 2 FXRKO mice were used
and at day 2, PCLS obtained from livers of 2 WT mice
and 3 FXRKO mice were used.
For the ATP assay and transcriptome analysis, WT-
PCLS and FXRKO-PCLS were exposed to 40 μM CsA
for 24 h. For histological examination, WT-PCLS and
FXRKO-PCLS were exposed to 40 μM CsA for 24 h and
48 h. CsA was added to the culture medium as a stock
solution in DMSO (final concentration of DMSO in the
medium was 0.1 % v/v). Slices incubated with 0.1 % v/v
DMSO served as control. These conditions were also
used in a previous work studying the effects of CsA in
mouse PCLS [11].
For q-PCR analysis, WT-PCLS and FXRKO-PCLS were
exposed for 24 h to 100 μM of CDCA dissolved in the
culture medium. This CDCA concentration was the
same as used in a previous study investigating effects of
CDCA in human PCLS [24]. PCLS incubated only in
the culture medium served as control for CDCA expos-
ure experiment.
ATP assay
To assess PCLS viability after the exposure experiments,
the ATP assay was performed. For each ATP assay three
co-cultured slices were placed in 400 μL Cell Lytic MT
buffer (Sigma, Zwijndrecht, the Netherlands). Slices were
homogenized (6500 g, 8 °C) two times for 15 s using a
tissue homogenizer (Precellys 24 Bertin Technologies,
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Labmakelaar Benelux B.V. Rotterdam, The Netherlands).
To remove cellular debris, the homogenates were centri-
fuged for 5 min (14,000 g, 8 °C) and the remaining super-
natant was divided into two portions of 200 μL. One
portion was mixed with 100 μL of ATP lytic buffer from
ATPlite kit (Perkin Elmer, Oosterhout, The Netherlands)
for ATP measurements and the second portion was stored
at −80 °C for protein measurements. ATP was measured
as described by the manufacturer using a microplate reader
(Synergy TM HT Multi Detection Microplate Reader,
Biotek Instruments Inc, Abcoude, the Netherlands) with
settings for luminescence 590/635 nm, top measurement,
and sensitivity 230. ATP measurements were performed
in technical duplicates and luminescence values were
recalculated into μM ATP in total liver slices extracts.
The protein concentration was measured using the
Bradford method (Protein assay, BioRad, Veenendaal, The
Netherlands). Protein samples of 2 μL were diluted 80
times in PBS and measured according to the manufac-
turer’s protocol. BSA was used as a standard and each
measurement was performed in duplicate. ATP con-
centration was normalized on mg of protein per slice.
ATP concentration is the mean ± SD of 5 independent
experiments.
Histology
Besides measurement of ATP levels, also histological
analysis was performed to examine the viability of the
slices after incubation. Slices were exposed for 24 and
48 h to 40 μM CsA or DMSO. For the 48 h cultures,
after 24 h the culture medium was replaced with fresh
medium supplemented with CsA or DMSO. After incu-
bation, slices were fixed in 4 % buffered formaldehyde
and embedded in paraffin. Next, the paraffin cross-sections
were prepared and stained with haematoxylin and eosin
(HE) according to Mayer’s protocol [25]. Sections of 3
independent experiments per each group were analysed
and photographed under a microscope with a 100-fold
magnification.
DNA microarray hybridizations
Gene expression analysis in PCLS incubated for 24 h
with CsA or DMSO was performed using the HT Mouse
Genome 430 PM array plate (s) using the Affymetrix
GeneTitan system (Affymetrix, Santa Clara, CA, USA).
RNA was extracted from co-cultured slices using the
RNeasy Tissue Mini Kit (Qiagen, Venlo, The Netherlands)
according to the manufacturer’s protocol. RNA concentra-
tion and purity were assessed using a NanoDrop ND-1000
spectrophotometer (Isogen IJsselstein, The Netherlands)
by measuring absorption ratios at 260/280 and 230/
280 nm. The integrity of the RNA samples was checked
using the Shimadzu MultiNA Bioanalyzer (Shimadzu,
Tokyo, Japan). Biotin- labelled cRNA was generated
from total RNA with the Affymetrix 3’IVT Express Kit
(Affymetrix, Santa Clara, CA, USA) according to the
manufacturer’s instructions with an input of 100 ng
total RNA. The Agilent Bioanalyzer (Agilent, Amstelveen,
the Netherlands) and the Shimadzu MultiNA Bioanalyzer
(Shimadzu,Tokyo, Japan) were used to examine the quality
of cRNA to confirm that the average fragment size was ac-
cording to Affymetrix’ specifications. For each sample,
7.5ug biotinylated cRNA was fragmented and hybridized
in a final concentration of 0.0375 ug /ul on the Affymetrix
HT Mouse genome 430 PM array (Affymetrix, Santa
Clara, CA, USA). After washing and staining by the
GeneTitan instrument (Affymetrix, Santa Clara, CA, USA)
using the Affymetrix HWS kit for Gene Titan, absolute
values of expression were calculated from the scanned
array using the Affymetrix Command Console v 3.2 soft-
ware. The data Quality Control was performed using the
Affymetrix Expression Console v 1.1 (Affymetrix, Santa
Clara, CA, USA) software to check whether all parameters
met the quality specifications. The Probe Logarithmic
Intensity Error Estimation (PLIER) algorithm method
was used for probe summarisation [26].
In order to monitor the sample independent control
and the performance of each individual sample during
hybridization, hybridization controls were added to the
hybridization mixture. To determine the biological vari-
ation between samples, the sample dependent controls
such as internal control genes, background values, and
average signals were used. In summary, all the data were
within data Quality Control thresholds, according to
the Affymetrix Expression Console specifications. Non-
normalized data in a form of the Cell Intensity File
(*.CEL) were re-annotated (EntrezGene htmg430pm_
Mm_ENTREZG) and the data were RMA normalized
[26]. The microarray data generated in this study were
deposited to gene expression omnibus (GEO) and the
GEO accession number is GSE63457 (data will be pub-
lic upon acceptance of the manuscript).
Identification of significantly affected genes
To identify genes significantly affected by CsA in WT-
PCLS and FXRKO-PCLS, the normalized data were log2
transformed, followed by analysis of variance (ANOVA)
with Benjamini-Hochberg correction for false discovery
rate (FDR). Genes were considered significant if FDR < =




MetaCore identifies pathways using a default enrichment
analysis. Genes significantly affected by CsA in WT-PCLS
and FXRKO-PCLS (FDR ≤0.05) were uploaded to
MetaCore for pathway analysis. The pathway analysis
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was performed using Functional Ontology Enrichment/
Pathways Maps default option in MetaCore for mouse.
The identified pathways were considered as significantly
affected by the treatment after FDR correction if FDR ≤
0.005.
Gene Ontology analysis (DAVID)
Genes significantly up- or down-regulated by CsA in
WT-PCLS and FXRKO-PCLS were uploaded separately
to Database for Annotation, Visualization, and Integrated
Discovery (DAVID) Bioinformatics Resource. In DAVID,
the Functional Annotation Clustering tool was used to
identify over-represented up and down-regulated Gene
Ontology (GO) terms [27, 28]. The Mouse Genome 430
2.0 was used as a background for the GO analysis. The
GO terms after FDR correction (Benjamini-Hochberg)
were selected at FDR ≤ 0.005 for further analysis and inter-
pretation. In addition we selected genes significantly af-
fected by CsA in WT-PCLS and FXRKO-PCLS identified
in the significant GO terms for further analysis by hier-
archical cluster analysis (HCA) and functional clustering
(see below).
Hierarchical clustering analysis
The differentially expressed genes extracted from significant
GO terms were analysed by hierarchical clustering analysis
(HCA) using an open access bioinformatics tool Genesis
(http://genome.tugraz.at/genesisserver/genesisserver_
description.shtml). In the analysis gene expression values
were log2 transformed and median centered, followed by
HCA using average linkage clustering in Genesis.
Gene functional clustering (STRING)
Significant genes extracted from the significant GO terms
were subjected to gene functional clustering with the
open access bioinformatics tool STRING (Search Tool
for the Retrieval of Interacting Genes/Proteins) version
8.2. STRING constructs functional networks using in-
formation from known and predicted protein-protein
interactions present in curated as well as experimental
databases [29].
q-PCR
Expression of selected known and novel candidate FXR
target genes was analysed in WT-PCLS and FXRKO-PCLS
exposed to CDCA or control for 24 h by q-PCR. The
q-PCR was performed using the Biorad CFX96 TM
Real-Time Detection System (Bio-Rad, Veenendaal, The
Netherlands) with the following cycling conditions:
15 min 95 °C followed by 40 cycles of 15 s 95 °C and
1 min 60 °C. Reactions were performed in 10 μl and
contained 20 ng cDNA, 1× TaqMan PCR Master Mix
(Applied Biosystems, Foster City, CA), and 250 nM probe
and 900 nM primer (for actinβ) or 1×TaqMan gene
expression assay (for the remaining genes) (Applied
Biosystems, Foster City, CA). A specific primer set for
actinβ (ACTB) was developed with Primer Express 1.5
(Applied Biosystems, Nieuwerkerk aan den IJssel, The
Netherlands) and sequences were as follows, probe:
TGT CCC TGT ATG CCT CTG GTC GTA CCA C,
forward primer: AGC CAT GTA CGT AGC CAT CCA,
and reverse primer: TCT CCG GAG TCC ATC ACA
ATG. Primers for: small heterodimer protein (Shp), bile
salt export pump (Bsep), fatty acid synthase (Fasn), cyto-
chrome P450, Subfamily VIIA (Cyp7a1, acyl-Coenzyme A
oxidase 2, branched chain (Acox2), acyl-Coenzyme A
dehydrogenase, short/branched chain (Acadsb), ELOVL
family member 6 (Elovl6), mitochondrial GTPase 1 homo-
log (Mtg1), aldehyde oxidase 1 (Aox1), peroxisome prolif-
erator activator receptor delta (Pparδ), and peroxisome
proliferator activated receptor gamma, coactivator 1 β
(Ppargc1b) were purchased from Applied Biosystems.
The commercial numbers of the Taqman assays and
additional information about the tested genes is given
in Additional file 1. Data were analyzed with SDS 2.0
software (Bio-Rad, Veenendaal, the Netherlands). For
each sample, the RT-PCR reaction was performed in
triplicate and the averages of the obtained threshold
cycle values (CT) were processed for further calculations.
To check for contaminating DNA, samples without re-
verse transcriptase (−RT reaction) were analysed as well.
For normalization ACTB was used. Relative expression
was calculated with Δ (Δ (CT))-method [30]. Expres-
sion of each gene is the mean ± SD of 5 independent
experiments.
Statistical analysis
A Mann–Whitney (IBM SPSS Statistics version 20) was
used to calculate differences between controls and slices
cultured with CsA in normalized ATP content as well as
to determine differences in gene expression measured by
q-PCR between CDCA treated slices and controls. The
cut off for statistical significance was set at a p-value ≤
0.05.
Results
Assessment of slice viability
Viability of WT-PCLS and FXRKO-PCLS exposed to
40 μM of CsA or DMSO for 24 h was assessed by deter-
mining ATP levels normalized on total protein content.
There was no statistically significant difference in the nor-
malized ATP content between WT-PCLS and FXRKO-
PCLS treated with DMSO or CsA indicating that exposure
of both types of slices to 40 μM CsA did not result in
cytotoxicity (Fig. 1).
To determine whether CsA treatment differentially
affected WT-PCLS and FXRKO-PCLS morphology, HE
staining was performed. WT-PCLS and FXRKO-PCLS
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were exposed to DMSO or CsA for 24 or 48 h. There
were no differences in morphology between WT-PCLS
and FXRKO-PCLS cultured in the presence of DMSO
for 24 and 48 h (Fig. 2a, e, c, and g respectively). There
were also no differences between WT-PCLS and FXRKO-
PCLS exposed to CsA for 24 and 48 h. However, the CsA
treated slices developed ballooned hepatocytes in the
outer layers of the slices (Fig. 2b and f, respectively). This
phenotype was aggravated in both types of PCLS exposed
to CsA for 48 h and there was no difference in the effect
of CsA related to the number or time of appearance of
ballooned hepatocytes between WT-PCLS and FXRKO-
PCLS (Fig. 2d and h, respectively).
Transcriptome analysis
Total RNA from WT-PCLS and FXRKO-PCLS treated
for 24 h with 40 μM of CsA or DMSO were used for DNA
microarray hybridizations and array data were analysed by
ANOVA with FDR correction. The analysis resulted in the
identification of 1549 genes that were significantly regu-
lated (FDR ≤ 0.05, absolute FC ≥1.5) by CsA in WT-PCLS
and FXRKO-PCLS in common (609 up- and 940 down-
regulated) (Fig. 3a and b). It was observed that FCs in ex-
pression of these genes were comparable in both types of
slices, indicating that quantitative effects of CsA were simi-
lar (GSE63457, Fig. 3c, and d). As shown in Fig. 3a and b,
in addition to the genes commonly regulated by CsA in
both WT-PCLS and FXRKO-PCLS, 303 genes were sig-
nificantly affected only in WT-PCLS (137 up- and 166
down-regulated) and 700 genes were uniquely affected
in FXRKO-PCLS (220 up- and 480 down-regulated).
Functional analysis of genes commonly regulated by CsA
in WT-PCLS and FXRKO-PCLS
The significantly affected genes were subjected to path-
way analysis in MetaCore. The pathway analysis of the
Fig 1 Viability of mouse liver slices upon treatment. Slices obtained from livers of WT and FXRKO mice (denoted as WT-PCLS and FXRKO-PCLS,
respectively) were incubated for 24 h with 40 μM of cyclosporin A (CsA) or vehicle control (DMSO). ATP content (nmol/mg of protein) in slices
treated with CsA was compared to control slices (DMSO). Each point is the mean ± SD of 5 independent experiments. None of the measured
parameters was significantly affected
HGFE
DCBA





FXRKO-PCLS CsA 48hFXRKO-PCLS DMSO 48h
Fig. 2 Histological analysis of liver slices treated with cyclosporin A (CsA). WT-PCLS (a-d) were cultured for 24 and 48 h in the presence of DMSO
(a and c) or 40 μM CsA (b and d). FXRKO-PCLS (e-h) were cultured for 24 and 48 h in the presence of DMSO (e and g) or 40 μM CsA (f and h)
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genes commonly regulated in WT-PCLS and FXRKO-
PCLS upon exposure to CsA led to identification of 29
significant pathways (18 up- and 11 down-regulated at
an FDR ≤ 0.005) (Table 1). All the identified pathways
were grouped into functional categories based on infor-
mation provided by the MetaCore classification tool. In
general, it was observed that the significantly upregulated
pathways clustered into “Endoplasmic reticulum stress”,
“Metabolic diseases”, and “Inflammation” and that the
most significantly upregulated pathway was represented
by “ER stress response pathway “(Fig. 4a, Table 1). The sig-
nificantly downregulated pathways could be clustered into
functional categories such as “Coagulation” and “Regula-
tion of energy metabolism” (Table 1). Examples of these
pathways were “Blood coagulation”, (Table 1) and “Bile
acids regulation of glucose and lipid metabolism via FXR”
(Fig. 4b, Table 1).
Next, genes significantly affected by CsA in WT-PCLS
and FXRKO-PCLS were subjected to GO enrichment ana-
lysis in DAVID. The analysis identified that GO processes
such as “ER”, “ER stress”, and “protein/vesicular transport”
were significantly upregulated (FDR < 0.005; Table 2).
While “coagulation”, “lipid metabolism”, and “protein pro-
cessing” were significantly downregulated (FDR < 0.005;
Fig. 3 Identification of significantly affected genes. To identify genes significantly affected by CsA in WT-PCLS and FXRKO-PCLS, analysis of variance
(ANOVA) was performed and corrected for FDR by the Benjamini test. Venn diagrams of significantly upregulated (FDR ≤0.05) and downregulated
(FDR≤ 0.05) genes in WT-PCLS and FXRKO-PCLS are presented in (a and b), respectively. The top 25 significantly upregulated and downregulated
genes are presented as heat maps in (c and d), respectively. Each heat map shows fold change (treatment vs. control) calculated in individual experiments
based on normalized gene expression values of DNA microarrays. WT-PCLS or WT indicates slices obtained from wild type (WT) mice. FXRKO-PCLS or KO
indicates slices obtained form Fxr-knockout (FXRKO) mice. Red color indicates upregulation and green shows downregulation
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Table 2). Overall, the results of the GO analysis were in
agreement with those of the MetaCore pathway analysis
and pointed to regulation of similar biological processes
including upregulation of ER stress and inflammation, and
downregulation of coagulation and energy metabolism.
Functional analysis of genes uniquely regulated in either
WT-PCLS or FXRKO-PCLS
In order to better understand the impact of Fxr defi-
ciency on CsA treatment, the genes uniquely regulated
in WT-PCLS or FXRKO-PCLS were subjected to pathway
and GO analyses. The pathway analysis did not identify
any significant pathways (FDR ≤ 0.005) in neither WT-
PCLS nor FXRKO-PCLS. However, with regard to GO
analysis, GO- processes related to “ECM” were signifi-
cantly downregulated (FDR ≤0.005) inWT-PCLS (Table 3).
In FXRKO-PCLS, GO- processes related to “inflamma-
tion” were significantly upregulated, while GO- processes
related to “mitochondrion” were significantly downregu-
lated (Table 3).
In order to gain more insight into functions of genes
identified in the GO processes uniquely regulated in
WT-PCLS or FXRKO-PCLS, genes significantly contribut-
ing to the GO enrichment were visualized as functional
networks and heat maps. In WT-PCLS gene clusters re-
lated to development/morphogenesis and ECM compo-
nents were identified (Fig. 5). In FXRKO-PCLS the
genes upregulated by CsA were clustered into different
Table 1 Pathway analysis of the commonly affected genes by CsA in WT-PCLS and FXRKO-PCLS
Functional category Pathways FDR In Data Total
Upregulation ER stress Endoplasmic reticulum stress response pathway 2.0E-08 16 55
ER stress Role of PKR in stress-induced apoptosis 3.2E-05 12 53
ER stress CFTR folding and maturation (normal and CF) 3.4E-05 8 21
ER stress APRIL and BAFF signaling 2.0E-03 8 39
ER stress ATM/ATR regulation of G1/S checkpoint 3.3E-03 7 32
ER stress Regulation of degradation of deltaF508-CFTR in CF 1.7E-05 11 39
ER stress wtCFTR traffic/ER-to-Golgi (normal) 5.0E-04 6 15
ER stress DeltaF508-CFTR traffic/ER-to-Golgi in CF 5.0E-04 6 15
ER stress RAB1A regulation pathway 1.8E-03 5 12
ER stress DeltaF508-CFTR traffic/Sorting endosome formation in CF 1.8E-03 7 28
ER stress Regulation of degradation of wtCFTR 1.9E-03 6 20
ER stress Proteolysis_Role of Parkin in the Ubiquitin-Proteasomal Pathway 4.3E-03 6 24
ER stress Clathrin-coated vesicle cycle 4.6E-03 10 71
Metabolic diseases Role of free fatty acids in obesity and type 2 diabetes 2.6E-04 10 45
Metabolic diseases Role of ER stress in obesity and type 2 diabetes 9.9E-04 10 54
Inflammation IL-17 signaling pathways 1.8E-03 10 60
Inflammation CD40 signaling 3.0E-03 10 65
Inflammation Role of PKR in stress-induced antiviral cell response 4.4E-03 9 57
Downregulation Coagulation Thromboxane A2 pathway signaling 4.7E-04 13 49
Coagulation Lectin induced complement pathway 4.7E-04 13 49
Coagulation HTR2A-induced activation of cPLA2 1.1E-03 11 43
Coagulation Blood coagulation 1.8E-03 10 39
Coagulation Classical complement pathway 3.4E-03 11 52
Coagulation MIF - the neuroendocrine-macrophage connector 4.2E-03 10 46
Coagulation Alternative complement pathway 4.6E-03 9 39
Regulation of energy metabolism CREB pathway 2.1E-03 11 49
Regulation of energy metabolism Regulation of lipid metabolism by niacin and isoprenaline 3.7E-03 10 45
Regulation of energy metabolism Bile acids regulation of glucose and lipid metabolism via FXR 3.7E-03 9 37
Regulation of energy metabolism PPAR pathway 3.7E-03 12 63
Metacore pathway analysis using significant genes (FDR ≤ 0.05) regulated by CsA in WT-PCLS and FXRKO-PCLS identified 18 significantly upregulated pathways
and 11 significantly downregulated pathways (FDR ≤ 0.005). The identified pathways are grouped into functional categories according to MetaCore pathway
classification tool and are presented in the first column. Next columns represent names of the identified pathways, FDR score, number of significantly regulated genes
identified in our study (“In data”), and the total number of genes belonging to the identified pathways (“Total”)
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pro-inflammatory processes, such as TNF and chemo-
kine signaling (Fig. 6), while the downregulated clusters
contained several genes involved in mitochondrial pro-
cesses such as β-oxidation, CoA metabolism, and genes
of the cytochrome P450 superfamily (Fig. 7).
Fxr deficiency and GO-terms related to mitochondrial
functions
In a further analysis we focused on genes identified in
the significant GO-processes related to mitochondrial func-
tions, which were uniquely downregulated in FXRKO-
PCLS upon CsA treatment (Table 3, Fig. 7). Based on these
findings, we speculated that some of these genes might play
a role in FXR signaling and/or represent novel FXR target
genes. To determine whether a subset of these genes is reg-
ulated by endogenous FXR ligand in an FXR dependent
manner, WT-PCLS and FXRKO-PCLS were exposed to
CDCA and gene expression was analysed by q-PCR. As
positive controls we measured the expression of known
FXR target genes such as Shp, Bsep, Fasn, and Cyp7a1 [2].
As putative FXR target genes identified in the present
study, we investigated the expression of Elovl6, Aox1,
Mtg1, and Acox2. In addition, we tested Pparδ, since some
of the genes downregulated by CsA in FXRKO-PCLS were
previously described as Pparδ target genes i.e. Aox1and
Ppargc1b [31]. As expected, in WT-PCLS, but not in
FXRKO-PCLS, the known FXR target genes including
Shp, Bsep, and Fasn were significantly upregulated by
CDCA treatment 1.9, 2.1, and 2.1 fold, respectively (p <
0.05) (Fig. 8a-c). Surprisingly, despite significant upreg-
ulation of Shp there was no downregulation of Cyp7a1
in WT-PCLS treated with CDCA, Fig. 8d. Although the
putative FXR targets i.e. Acox2 and Elovl6 tended to be
upregulated by CDCA in an FXR-dependent manner, it
did not reach a significant difference, Fig. 8e-f. Further-
more, it was observed that Pparδ and Ppargc1b were
significantly induced by CDCA treatment in an FXR-
dependent manner (2.3 and 1.9-fold respectively, p < 0.05),
therefore suggesting that these genes are regulated by
FXR, Fig. 8i-j.
Discussion
In the present study we investigated the impact of Fxr
deficiency on the effects of the model hepatotoxicant CsA
in mouse PCLS. It was anticipated that Fxr deficiency
could aggravate the hepatotoxicity of CsA and pinpoint to
novel genes/processes regulated by FXR.
Fig. 4 Effects of CsA on the expression of genes involved in endoplasmic reticulum stress and FXR-regulated pathways in WT-PCLS and FXRKO-
PCLS. Pathway analysis was performed in MetaCore using as input significant genes (FDR≤ 0.05) regulated by CsA in WT-PCLS and FXRKO-PCLS.
Pathways were considered as significant if FDR ≤0.005. Among the most significantly regulated pathways were “Endoplasmic reticulum (ER) stress
response pathway” (a) and “Bile acids regulation of glucose and lipid metabolism via FXR “(b). Blue and red bars indicate down-and up-regulation
respectively of significantly affected genes. Numbers 1 and 2 below the bars indicate WT-PCLS and FXRKO-PCLS, respectively. Each bar represents
average fold change of gene expression (treatment vs. control) in liver slices from five mice. For an explanation of the other MetaCore symbols is
referred to http://pathwaymaps.com/pdf/MC_legend.pdf
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Measurement of cellular ATP levels revealed that the
applied CsA concentration did not affect the viability of
either WT-PCLS or FXRKO-PCLS, suggesting a com-
parable tolerance of both types of slices to 40 μM CsA
(Fig. 1). Despite application of non-toxic concentrations
of CsA, its treatment triggered ballooning of hepato-
cytes, which indicates on induction of inflammation and
apoptosis in WT-PCLS and FXRKO-PCLS (Fig. 2).
However, the ballooning occurred only in the outer layers
of both types of PCLS which, compared to the inner
layers, likely are exposed to higher CsA concentration.
These findings are in agreement with previous work
showing that the same phenotype developed upon treat-
ment of mouse PCLS with CsA [11] and indicate that
the response of WT-PCLS and FXRKO-PCLS to CsA is
comparable.
The transcriptome analysis showed that in both WT-
PCLS and FXRKO-PCLS, CsA upregulated pathways
related to ER stress, protein/vesicular transport, NFκb
signaling, and inflammation (Figs. 3c and 4a, Table 1).
These findings are in line with the literature reporting
that CsA induces oxidative stress, unfolded protein re-
sponse, and inflammation [11, 19, 32]. However, the lack
of major differences in response of WT-PCLS and
FXRKO-PCLS to CsA seems to be in contrast to find-
ings of Wang and colleagues who demonstrated that
Fxr-deficiency in Fxr-KO mice and human hepatocytes
have significantly increased hepatotoxicity upon exposure
to other inducers of oxidative stress represented by carbon
tetrachloride (CCl4) and hydrogen peroxide (H2O2) re-
spectively [33]. It was shown that oxidative stress in-
duced by CCl4 or H2O2 inhibit the binding of FXR to
Table 2 Gene ontology (GO) analysis of the commonly affected genes by CsA in WT-PCLS and FXRKO-PCLS
General function GO process FDR
Upregulation ER GO:0005783 ~ endoplasmic reticulum 2.8E-25
ER GO:0044432 ~ endoplasmic reticulum part 4.4E-15
ER GO:0031974 ~membrane-enclosed lumen 3.0E-11
ER GO:0070013 ~ intracellular organelle lumen 5.6E-10
ER GO:0005788 ~ endoplasmic reticulum lumen 4.4E-09
ER GO:0042175 ~ nuclear envelope-endoplasmic reticulum network 2.5E-08
ER GO:0005789 ~ endoplasmic reticulum membrane 2.9E-07
ER GO:0012505 ~ endomembrane system 6.6E-05
ER stress GO:0006986 ~ response to unfolded protein 2.2E-04
ER stress GO:0034976 ~ response to endoplasmic reticulum stress 2.2E-03
Protein/vesicular transport GO:0045184 ~ establishment of protein localization 8.1E-08
Protein/vesicular transport GO:0015031 ~ protein transport 9.7E-08
Protein/vesicular transport GO:0008104 ~ protein localization 5.0E-07
Protein/vesicular transport GO:0031982 ~ vesicle 1.3E-03
Protein/vesicular transport GO:0016192 ~ vesicle-mediated transport 1.7E-03
Protein/vesicular transport GO:0046907 ~ intracellular transport 2.1E-03
Protein/vesicular transport GO:0016023 ~ cytoplasmic membrane-bounded vesicle 2.1E-03
Protein/vesicular transport GO:0031988 ~membrane-bounded vesicle 2.5E-03
Protein/vesicular transport GO:0031410 ~ cytoplasmic vesicle 4.0E-03
Downreg. Coagulation GO:0009611 ~ response to wounding 2.4E-06
Coagulation GO:0006956 ~ complement activation 4.1E-06
Coagulation GO:0006958 ~ complement activation, classical pathway 9.8E-04
Lipid metabolism GO:0006644 ~ phospholipid metabolic process 5.0E-04
Lipid metabolism GO:0016042 ~ lipid catabolic process 8.6E-04
Lipid metabolism GO:0006631 ~ fatty acid metabolic process 9.6E-04
Lipid metabolism GO:0006775 ~ fat-soluble vitamin metabolic process 2.5E-03
Protein processing GO:0051605 ~ protein maturation by peptide bond cleavage 1.8E-05
Protein processing GO:0051604 ~ protein maturation 1.5E-04
GO analysis of the significant genes (FDR ≤ 0.05) regulated by Cyclosporin A in WT-PCLS and FXRKO-PCLS. GO analysis was performed in DAVID and GO process
was considered as significant if FDR ≤ 0.005. In addition, the individual GO processes were grouped according to their general function and these groups are
depicted in column denoted as “General function”
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Table 3 GO analysis of genes uniquely regulated in WT-PCLS or FXRKO-PCLS
General process GO process (WT-PCLS) FDR Direction of change
WT-PCLS ECM GO:0031012 ~ extracellular matrix 9.4E-10 Downregulation
ECM GO:0005578 ~ proteinaceous extracellular matrix 2.0E-09 Downregulation
ECM GO:0044421 ~ extracellular region part 1.5E-06 Downregulation
ECM GO:0005576 ~ extracellular region 2.0E-04 Downregulation
FXRKO-PCLS Inflammation GO:0005125 ~ cytokine activity 6.1E-05 Upregulation
Inflammation GO:0005615 ~ extracellular space 4.6E-03 Upregulation
Inflammation GO:0006935 ~ chemotaxis 9.8E-03 Upregulation
Inflammation GO:0042330 ~ taxis 9.8E-03 Upregulation
Mitochondrial functions GO:0005739 ~mitochondrion 2.0E-11 Downregulation
Mitochondrial functions GO:0048037 ~ cofactor binding 1.5E-03 Downregulation
Mitochondrial functions GO:0044429 ~mitochondrial part 2.9E-03 Downregulation
GO analysis of the significant genes (FDR ≤ 0.05) uniquely regulated by CsA in WT-PCLS or FXRKO-PCLS. GO analysis was performed in DAVID and GO process was
considered as significant if FDR ≤ 0.005. In addition, the GO processes were grouped according to their general function and these groups are depicted in column




Fig 5 Functional and hierarchical clustering analysis of genes identified in GO processes related to “ECM” uniquely regulated in WT-PCLS. Genes
identified in the significant GO-processes (FDR≤ 0.005) related to “ECM” in WT-PCLS are presented as a network and a heat map. The network
consists of 3 functional clusters shown as circles and denoted as: metalloproteinases (1), collagens (2), and development/morphogenesis (3).
Connected nodes within the functional clusters indicate known gene-gene interactions and genes for which gene-gene interactions are unknown are
presented as unconnected nodes. Thicker lines represent stronger associations between genes. Inter-cluster edges are represented by dashed lines.
The heat map is the result of hierarchical clustering of log2, median centered, gene expression values in slices obtained from individual mice. Red and
green indicate expression higher and lower, respectively, than the average expression of all samples within the heat map. WT stands for control
(DMSO-treated) slices obtained from WT mice. WTCSA stands for CsA treated slices obtained from WT mice. KO stands for control (DMSO)
slices obtained from FXRKO mice. KOCSA stands for CsA treated slices obtained from FXRKO mice
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FXRE by increased poly (ADP-ribosyl) ation of FXR
catalysed by poly (ADP-ribose) polymerase 1 (PARP1),
which alters FXR conformation leading to dissociation
of FXR from FXRE and thereby suppresses expression
of FXR target genes involved in hepatoprotection [33].
The lack of differences between FXRKO-PCLS and
WT-PCLS with respect to regulation of stress response
pathways and hepatotoxic effects in our study and the
observations of Wang and colleagues could be explained
by (i) differences in the mechanism of action between CsA
and CCl4/H2O2 and/or (ii) model-dependent differences.
However, a recent study investigating effects of CsA in
HepaRG cells showed that 50uM CsA induces oxidative
stress as early as 15 min leading to irreversible alterna-
tions of efflux and uptake of BA co-occurring with disor-
ganisation of F-actin microfilaments and bile canaliculi
[34]. These early events were followed by altered expres-
sion of genes related to oxidative stress (at 6 h) and
genes controlling bile acid homeostasis (at 24 h). There-
fore, based on the results of Sharanek et al.[34], it could
be anticipated that in our study the lack of differences in
morphology between WT-PCLS and FXR-PCLS results
from early and irreversible cytotoxic effects of CsA, which
are gene-expression independent and cannot be compen-
sated at later time points by potential hepatoprotective
effects of FXR. From the other hand, the slightly worse
hepatotoxic gene expression profile in FXRKO-PCLS vs.
WT-PCLS, could reflect the disability of FXRKO-PCLS to
involve the FXR-dependent hepatoprotective mechanism
that controls expression of gens involved in inflammation
and mitochondrial functions.
As mentioned above, we observed upregulation of sev-
eral genes encoding pro-inflammatory cytokines such as
Il-6, Csf3 (~3-6-fold upregulated), and Il-23. The latter
gene was the most upregulated one in both types of PCLS
(above 20 fold; Fig. 3c). IL-23 is produced by dendritic and
Kupffer cells upon stimulation with pro-inflammatory
stimuli e.g. LPS [35]. IL-23 together with IL-6 activates
naive CD4 + T cells to differentiate into highly pro-
inflammatory Th17 cells producing IL-17 that further
enhances expression of IL-1, IL-6, TNFα, and NOS-2 [35].
However in our study, despite upregulation of Il-6 and
Il-23, we did not observe upregulation of Il-17 in both




Fig. 6 Functional and hierarchical clustering analysis of genes identified in GO processes related to “inflammation” uniquely regulated in FXRKO-PCLS.
Genes identified in the significant GO-processes (FDR≤ 0.005) related to “inflammation” in FXRKO-PCLS are presented as a network and a heat map.
The network consists of 3 functional clusters shown as circles and denoted as: immunomodulation (1), chemokine signaling (2), and TNF signaling (3).
The heat map is the result of hierarchical clustering of log2, median centered, gene expression values in slices obtained from individual mice.
For explanation of the lines, spheres, the heat map, and abbreviations, see Fig. 5
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that CsA inhibited maturation of CD4 + T cells into Th17.
However it is also possible that maturation of Th17 does
not occur in PCLS, since CD4 + T cells might be absent in
our model [36]. In this context it is noteworthy to men-
tion that despite CsA therapy, there are patients with high
serum levels of IL-23 and IL-17 suffering from acute
organ rejection in contrast to patients with low serum
levels of IL-23 and IL-17 who accept graft [37]. On the
basis of these literature observations, it can be envisaged
that in case the immunosuppressive effect of CsA (i.e.
inhibition of CD4 + T/Th17 transition) is overruled by
the hepatotoxic effects of CsA (i.e. stimulation of IL-23
expression), then CsA could induce the IL-23-dependent
maturation of highly pro-inflammatory Th17 cells and
trigger organ rejection.
Furthermore, WT-PCLS and FXRKO-PCLS significantly
downregulated expression of key genes and pathways in-
volved in regulation of energy metabolism such as Hnf4α,
Lxrα, Rxrα, “Bile acids regulation of glucose and lipid me-
tabolism via FXR”, and “PPAR pathway” (Fig. 4b, Table 1).
These observations suggest that CsA can impair lipid and
glucose homeostasis and are in line with literature reports
linking CsA therapy with the development of metabolic
diseases [15–17, 38]. These hepatotoxic effects can be re-
lated to CsA-driven upregulation of NFκb signaling and
inflammation (Figs. 3c and 4a, Table 1), which are known
to downregulate expression of different nuclear receptors
and their target genes [24, 39, 40].
Moreover, in WT-PCLS and FXRKO-PCLS CsA sig-










Fig. 7 Functional and hierarchical clustering analysis of genes identified in GO processes related to “mitochondrion” uniquely regulated in
FXRKO-PCLS. Genes identified in the significant GO-processes (FDR ≤ 0.005) related to “mitochondrion” in FXRKO-PCLS are presented as a
network and a heat map. The network consists of 9 functional clusters shown as circles and denoted as: protein/amino acid (aa) processing n
(1), NADH dehydrogenases (2), mitochondrial transporters (3), β-oxidation (4), CoA metabolism (5), mitochondrial ribosomal proteins (6),
glucose metabolism (7), mitochondrial homeostasis (8), and xenobiotics metabolism (9). The heat map is the result of hierarchical clustering of
log2, median centered, gene expression values in slices obtained from individual mice. For explanation of the lines, spheres, the heat map,
and abbreviations, see Fig. 5
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(Table 1). This finding is in line with previously reported
occurrence of haemorrhages in patients during CsA
therapy [41].
Analysis of the genes uniquely downregulated by CsA
in WT-PCLS revealed GO processes related to “ECM”
(Table 3, Fig. 5). The fact that this downregulation oc-
curred only in WT-PCLS points towards different effects
of CsA on cellular signaling in the presence/absence of
FXR. However, it is difficult to explain its exact meaning
in the context of FXR signaling due to the lack of any lit-
erature data exploring effects of FXR on genes belonging
to ECM.
Specifically in FXRKO-PCLS, CsA treatment upregu-
lated GO processes related to “inflammation” and down-
regulated GO processes related to “mitochondrial functions”
(Table 3, Figs. 6 and 7). With regard to the upregulation
of GO processes related to “inflammation”, this finding
is in line with known features of FXRKO mice, which
display exaggerated response to pro-inflammatory stimuli
[42, 43]. The significant downregulation of GO processes
related to “mitochondrial functions” in FXRKO-PCLS
points towards involvement of FXR in maintaining of
mitochondrial functions. Consistent with this notion, re-
cently it was reported that a synthetic FXR ligand 6-ethyl
CDCA (6-ECDCA) upregulated several mitochondrial
proteins in liver [44]. Moreover, Lee et al. reported
that during oxidative stress, activation of FXR reduced
mitochondrial dysfunction in hepatocytes [45]. Although,
we did not confirm by q-PCR that the selected genes iden-
tified within the GO terms related to “mitochondrial
functions” were significantly upregulated by CDCA in
an FXR-dependent manner, we cannot exclude that such
an upregulation could occur under certain physiological
challenge (e.g. oxidative stress) or using an FXR-ligand
other than CDCA. Based on our finding that the master
regulator of mitochondrial functions and inflammation
Pparδ and its target gene Ppargc1b [31, 46, 47] were sig-
nificantly upregulated by CDCA in an FXR dependent
manner (Fig. 8i-j), it can be speculated that the involve-
ment of FXR in regulation of mitochondrial functions and
inflammation could occur via an FXR-PPARδ crosstalk.
With regard to the application of mouse WT-/FXRKO-
PCLS to study FXR signaling in the liver, this model seems
to have some limitations. Although selected known FXR
target genes, such as Shp, Bsep, and Fasn were significantly
upregulated by CDCA in an FXR-dependent manner, we
did not observe a downregulation of Cyp7a1 (despite sig-
nificant upregulation of Shp). This finding indicates that
PCLS might lack other factors involved in Cyp7a1 inhib-
ition such as intestinal Fgf15 [48]. A similar phenomenon
Fig. 8 Validation of putative FXR target genes by q-PCR. WT-PCLS and FXRKO-PCLS were exposed for 24 h to chenodeoxycholic acid (CDCA) or
vehicle control (ctr). Q-PCR was used to measure mRNA expression relative to actin β of known FXR target genes (Shp, Bsep, Fas, Cyp7a1, a-d)
and putative FXR target genes (Acox2, Elovl6, Mtg1, Aox1, Pparδ, and Ppargc1b, e-j). Each condition (X-axis) is represented by 5 independent
experiments. Relative gene expression compared to actin β is plotted on Y-axis. Asterisk indicates gene expression significantly different from
controls according to Mann–Whitney-test (p < 0.05)
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was observed in regulation of NTCP in human PCLS,
where despite upregulation of SHP by CDCA, no repres-
sion of NTCP occurred [24]. These observations indicate
therefore that PCLS may not be suitable to study genes
regulated by trans-repression and/or cross-talk with extra-
hepatic tissues. However, our finding that Cyp7a1 basal ex-
pression was clearly higher in FXRKO-PCLS compared to
WT-PCLS (Fig. 8d), indicates that features of FXRKO
mouse are also preserved in PCLS [23].
Conclusions
In summary, our study shows that, although FXR plays a
central role in regulation of energy metabolism, no major
differences in response to CsA could be observed between
WT-PCLS and FXRKO-PCLS in regulation of processes
involved in lipid and glucose metabolism. This finding
indicates that CsA does not directly affect FXR func-
tions in relation to the above mentioned processes.
However, the CsA- induced upregulation of additional
pro-inflammatory genes/processes and the downregulation
of genes/processes involved in mitochondrial functions in
FXRKO-PCLS only, indicate that FXR can be hepatopro-
tective by controlling inflammation and mitochondrial
functions, possibly involving a crosstalk between FXR
and PPARδ.
Additional file
Additional file 1: Validation of known and putative Fxr target genes
by q-PCR. Information about primers and functions of genes used in q-PCR
to test expression of known and novel putative FXR target genes in
WT-PCLS and FXRKO-PCLS exposed to endogenous FXR ligand. Numbers of
Taqman assays are given in column “Taqman assay”. Information
about functions of the tested genes is according to Gene Cards
http://www.genecards.org/. (PPTX 103 kb)
Abbreviations
FXR: Farnesoid X receptor; PCLS: Precision cut liver slices; KO: Knockout;
WT: Wild type; CsA: Cyclosporin A; BA: Bile acids; CDCA: Chenodeoxycholic
acid; PPAR: Peroxisome proliferator- activated receptor; RXR: Retinoid X
receptor; FXRE: Farnesoid X receptor response elements; BSEP: Bile salt
export pump; BAAT: Bile acid-CoA:amino acid N-acyltransferase;
MDR3: Multidrug resistance protein 3; Cyp7a1: Cholesterol-7α-hydroxylase;
Shp: Small heterodimer partner; Lrh-1: Liver receptor homolog-1; Lxr liver: X
receptor; Hnf4α: Hepatocyte nuclear factor 4 α; Pepck: Phosphoenolpyruvate
carboxykinase; G6Pase: Glucose 6 phosphatase; ER: Endoplasmatic reticulum;
(NF)κB: Nuclear factor κB; PBS: Phosphate buffered saline; DMSO: Dimethyl
sulfoxide; KHB: Krebs-Henseleit Buffer; HEPES: (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid); GO: Gene ontology; DAVID: The database for
annotation, visualization, and integrated discovery; FDR: False discovery rate;
SD: Standard deviation; RMA: Robust Multiarray Averaging; HCA: Hierarchical
clustering analysis; PARP1: Poly (ADP-ribose) polymerase 1; ADP: Adenosine
diphosphate; CCl4: Carbon tetrachloride; H2O2: Hydrogen peroxide.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ESZ designed the study, analysed data, and wrote the manuscript. TP provided
bioinformatics support. AACMP contributed to the study design and
preparation of the manuscript. All authors read and approved the final
manuscript.
Acknowledgment
We would like to thank Folkert Kuipers for a kind donation of FXRKO and WT
mice, Juul Baller and Angelika Jurdzinski for assistance in transfer of the animals,
Judith Hulsman for assistance in handling of the animals, as well as Maria Groot
and Jan Ossenkoppele for carrying out the histological experiments.
Funding
This work was supported by the Netherlands Genomics Initiative, the
Netherlands Organisation for Scientific Research, and the Netherlands
Toxicogenomics Centre (grant number 05060510).
Author details
1RIKILT - Institute of Food Safety/Wageningen UR, Akkermaalsbos 2, P.O. Box
2306700 AE Wageningen, The Netherlands. 2Centre for Health Protection,
National Institute for Public Health and the Environment (GZB, RIVM),
Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands.
3RIKILT-Institute of Food Safety/Wageningen UR, Akkermaalsbos 2, 6708 WB
Wageningen, The Netherlands.
Received: 26 November 2014 Accepted: 12 October 2015
References
1. Huber RM, Murphy K, Miao B, Link JR, Cunningham MR, Rupar MJ, et al.
Generation of multiple farnesoid-X-receptor isoforms through the use of
alternative promoters. Gene. 2002;290(1–2):35–43.
2. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile
acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147–91.
3. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the
treatment of dyslipidemia and cardiovascular disease. J Lipid Res.
2012;53(9):1723–37.
4. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted
disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid
homeostasis. Cell. 2000;102(6):731–44.
5. Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH,
et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism
during the fasting-refeeding transition. J Biol Chem. 2005;280(33):29971–9.
6. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, et al.
Regulation of carbohydrate metabolism by the farnesoid X receptor.
Endocrinology. 2005;146(3):984–91.
7. Meng Z, Wang Y, Wang L, Jin W, Liu N, Pan H, et al. FXR regulates liver
repair after CCl4-induced toxic injury. Mol Endocrinol. 2010;24(5):886–97.
8. De Graaf I, Olinga P, De Jager MH, Merema MT, De KR, Van De Kerkhof EG,
et al. Preparation and incubation of precision-cut liver and intestinal slices
for application in drug metabolism and toxicity studies. NatProtoc.
2010;5(9):1540–51.
9. Fiorucci S, Cipriani S, Mencarelli A, Renga B, Distrutti E, Baldelli F. Counter-
regulatory role of bile acid activated receptors in immunity and inflammation.
Curr Mol Med. 2010;10(6):579–95.
10. Li Z, Kruijt JK, van der Sluis RJ, Van Berkel TJ, Hoekstra M. Nuclear receptor
atlas of female mouse liver parenchymal, endothelial, and Kupffer cells.
Physiol Genomics. 2013;45(7):268–75.
11. Szalowska E, Stoopen G, Groot MJ, Hendriksen PJ, Peijnenburg AA. Treatment of
mouse liver slices with cholestatic hepatotoxicants results in down-regulation of
Fxr and its target genes. BMC Med Genet. 2013;6(1):39.
12. Calne RY. Immunosuppression for organ grafting – observations on
cyclosporin A. Immunol Rev. 1979;46:113–24.
13. Bennett WM, Norman DJ. Action and toxicity of cyclosporine. Annu Rev
Med. 1986;37:215–24.
14. Rezzani R. Exploring cyclosporine A-side effects and the protective role-played
by antioxidants: the morphological and immunohistochemical studies.
HistolHistopathol. 2006;21(3):301–16.
15. Dandel M, Lehmkuhl HB, Knosalla C, Hetzer R. Impact of different long-term
maintenance immunosuppressive therapy strategies on patients’ outcome
after heart transplantation. TransplImmunol. 2010;23(3):93–103.
16. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ. Posttransplant
metabolic syndrome: an epidemic waiting to happen. Liver Transplant.
2009;15(12):1662–70.
Szalowska et al. BMC Genomics  (2015) 16:822 Page 15 of 16
17. Hulzebos CV, Bijleveld CM, Stellaard F, Kuipers F, Fidler V, Slooff MJ, et al.
Cyclosporine A-induced reduction of bile salt synthesis associated with
increased plasma lipids in children after liver transplantation. Liver
Transplant. 2004;10(7):872–80.
18. Wolf A, Trendelenburg CF, Ez Fernandez C, Prieto P, Houy S, Trommer WE, et al.
Cyclosporine A-induced oxidative stress in rat hepatocytes. JPharmacolExpTher.
1997;280(3):1328–34.
19. van Summeren A, Renes J, Bouwman FG, Noben JP, van Delft JH, Kleinjans JC,
et al. Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells.
ToxicolSci. 2011;120(1):109–22.
20. Barth A, Braun J, Muller D. Influence of Verapamil and Cyclosporin A on
bile acid metabolism and transport in rat liver slices. ExpToxicolPathol.
2006;58(1):31–7.
21. Chanussot F, Benkoel L. Prevention by dietary (n-6) polyunsaturated
phosphatidylcholines of intrahepatic cholestasis induced by cyclosporine A
in animals. Life Sci. 2003;73(4):381–92.
22. Kienhuis AS, Vitins AP, Pennings JL, Pronk TE, Speksnijder EN, Roodbergen M,
et al. Cyclosporine A treated in vitro models induce cholestasis response
through comparison of phenotype-directed gene expression analysis of in vivo
Cyclosporine A-induced cholestasis. Toxicol Lett. 2013;221(3):225–36.
23. Kok T, Hulzebos CV, Wolters H, Havinga R, Agellon LB, Stellaard F, et al.
Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice:
efficient intestinal bile salt absorption in the absence of ileal bile acid-binding
protein. JBiolChem. 2003;278(43):41930–7.
24. Jung D, Elferink MG, Stellaard F, Groothuis GM. Analysis of bile acid-induced
regulation of FXR target genes in human liver slices. Liver Int. 2007;27(1):137–44.
25. Groot MJ, Ossenkoppele JS, Bakker R, Pfaffl MW, Meyer HH, Nielen MW.
Reference histology of veal calf genital and endocrine tissues - an update for
screening on hormonal growth promoters. JVetMedA Physiol PatholClinMed.
2007;54(5):238–46.
26. Qu Y, He F, Chen Y. Different effects of the probe summarization
algorithms PLIER and RMA on high-level analysis of Affymetrix exon
arrays. BMCBioinformatics. 2010;11:211.
27. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID:
Database for Annotation, Visualization, and Integrated Discovery. Genome
Biol. 2003;4(5):3.
28. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis
of large gene lists using DAVID bioinformatics resources. Nat Protoc.
2009;4(1):44–57.
29. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al.
STRING v9.1: protein-protein interaction networks, with increased coverage
and integration. Nucleic Acids Res. 2013;41(Database issue):D808–15.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods.
2001;25(4):402–8.
31. Reilly SM, Lee CH. PPAR delta as a therapeutic target in metabolic disease.
FEBS Lett. 2008;582(1):26–31.
32. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. JHepatol.
2011;54(4):795–809.
33. Wang C, Zhang F, Wang L, Zhang Y, Li X, Huang K, et al. Poly(ADP-ribose)
polymerase 1 promotes oxidative-stress-induced liver cell death via
suppressing farnesoid X receptor alpha. Mol Cell Biol. 2013;33(22):4492–503.
34. Sharanek A, Azzi PB, Al-Attrache H, Savary CC, Humbert L, Rainteau D, et al.
Different dose-dependent mechanisms are involved in early cyclosporine
a-induced cholestatic effects in hepaRG cells. Toxicol Sci. 2014;141(1):244–53.
35. Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, et al. Pivotal
roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory
diseases. Clin Dev Immunol. 2013;2013:968549.
36. Oo YH, Shetty S, Adams DH. The role of chemokines in the recruitment of
lymphocytes to the liver. DigDis. 2010;28(1):31–44.
37. Fabrega E, Lopez-Hoyos M, San Segundo D, Casafont F, Pons-Romero F.
Changes in the serum levels of interleukin-17/interleukin-23 during acute
rejection in liver transplantation. Liver Transplant. 2009;15(6):629–33.
38. Krentz AJ, Dousset B, Mayer D, McMaster P, Buckels J, Cramb R, et al.
Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients.
Diabetes. 1993;42(12):1753–9.
39. Kim MS, Shigenaga J, Moser A, Feingold K, Grunfeld C. Repression of farnesoid X
receptor during the acute phase response. J Biol Chem. 2003;278(11):8988–95.
40. Kim MS, Sweeney TR, Shigenaga JK, Chui LG, Moser A, Grunfeld C, et al.
Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha,
PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and
PGC-1beta in liver cells. Metab Clin Exp. 2007;56(2):267–79.
41. Wang WL, Yang ZF, Lo CM, Liu CL, Fan ST. Intracerebral hemorrhage after
liver transplantation. Liver Transplant. 2000;6(3):345–8.
42. Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X
receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.
Hepatology. 2008;48(5):1632–43.
43. Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450
attenuates liver inflammation and fibrosis in murine model of non-alcoholic
steatohepatitis. J Hepatol. 2009;51(2):380–8.
44. Gardmo C, Tamburro A, Modica S, Moschetta A. Proteomics for the
discovery of nuclear bile acid receptor FXR targets. Biochim Biophys Acta.
2011;1812(8):836–41.
45. Lee CG, Kim YW, Kim EH, Meng Z, Huang W, Hwang SJ, et al. Farnesoid X
receptor protects hepatocytes from injury by repressing miR-199a-3p, which
increases levels of LKB1. Gastroenterology. 2012;142(5):1206–17. e1207.
46. Serrano-Marco L, Barroso E, El Kochairi I, Palomer X, Michalik L, Wahli W,
et al. The peroxisome proliferator-activated receptor (PPAR) beta/delta
agonist GW501516 inhibits IL-6-induced signal transducer and activator of
transcription 3 (STAT3) activation and insulin resistance in human liver cells.
Diabetologia. 2012;55(3):743–51.
47. Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, et al.
Hepato-protective effects of the dual PPARalpha/delta agonist GFT505
in rodent models of NAFLD/NASH. Hepatology. 2013;58(6):1941–52.
doi:10.1002/hep.26461. Epub 2013 Oct 29.
48. Claudel T, Zollner G, Wagner M, Trauner M. Role of nuclear receptors for bile
acid metabolism, bile secretion, cholestasis, and gallstone disease. Biochim
Biophys Acta. 2011;1812(8):867–78.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Szalowska et al. BMC Genomics  (2015) 16:822 Page 16 of 16
